Skip to main content

Table 2. Reported results of checkpoint blockade in EOC

From: Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)

Agent

Trial number

Disease status

Phase

N

Results (N; duration)

Ipilimumab

NCT01611558

Recurrent

II

40

10% BRR (4; N/A)

BMS-936559 (anti-PD-L1)

NCT00729664

Advanced stage

I

17

6% PR (1; 1.3+ months)

15% SD (3; 6+ months)

Nivolumab

UMIN0005714

Pt-resistant

Relapsed

II

2

10% CR (2; 11+ months)

5% PR (1; 11+ months)

30% SD (6; 1 for 11+ months)

Pembrolizumab

NCT02054806

Advanced stage

PD-L1+

Ib

26

4% CR (1; 6+ months)

8% PR (2; 6+ months)

23% SD (8; 2 for 6+ months)

Avelumab

NCT01772004

Pt-resistant

Recurrent

Ib

124

10% PR (12; 4 for 6+ months)

44% SD (55; N/A)

Durvalumab (+ olaparib)

NCT02484404

Recurrent

I/II

10

PR (1; 11+ months)

SD (7; 4+ months)

  1. Clinical trials of checkpoint inhibitors in endometrial ovarian cancer